Product Information
TRIFLUOPERAZINE 5 MG TABLET is a generic product labeled by Mylan Institutional LLC, priced at $0.8600 per EA under NDC 51079057420. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jul 7, 1997. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Mylan Institutional LLCNDC
51079057420
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TRIFLUOPERAZINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA040209FDA Approved
7/7/1997
TE Code
AB
On Market Since
3/4/1998
Pharmacological Classes
Price Statistics
The NADAC for TRIFLUOPERAZINE 5 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 106.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8600 per EA |
|---|---|
| All-time high | $1.2797 (Apr 15, 2015) |
| All-time low | $0.4172 (Nov 28, 2013) |
| 52-week high | $0.9301 |
| 52-week low | $0.7087 |
| Median price | $0.9194 |
| Average price | $0.9245 |
| Largest weekly change | +109.5% (Dec 18, 2013) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Institutional LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
trifluoperazine hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Phenothiazine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TRIFLUOPERAZINE 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRIFLUOPERAZINE 5 MG TABLET, manufactured by Mylan Institutional LLC, is $0.8600 per EA (NDC 51079057420), effective Sep 30, 2026.
How has the price of TRIFLUOPERAZINE 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for TRIFLUOPERAZINE 5 MG TABLET has risen 106.1%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for TRIFLUOPERAZINE 5 MG TABLET?
Since Nov 28, 2013, the NADAC for TRIFLUOPERAZINE 5 MG TABLET has ranged from a low of $0.4172 (Nov 28, 2013) to a high of $1.2797 (Apr 15, 2015), with a median of $0.9194 per EA.
Are there cheaper alternatives to TRIFLUOPERAZINE 5 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TRIFLUOPERAZINE 5 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TRIFLUOPERAZINE 5 MG TABLET?
TRIFLUOPERAZINE 5 MG TABLET (NDC 51079057420) is labeled by Mylan Institutional LLC, and CMS classifies it as a generic product.